医師の一分

アクセスカウンタ

zoom RSS アルツハイマー病の診断造影剤を承認/FDA

<<   作成日時 : 2012/04/09 23:49   >>

なるほど(納得、参考になった、ヘー) ブログ気持玉 3 / トラックバック 0 / コメント 0

 FDAはアルツハイマー病を診断するために脳内プラークを検出するイーライリリー社のAmyvidと呼ばれる放射性造影物質を承認した。
 脳に蓄積するβアミロイドと呼ばれる毒性タンパク質の塊に付着することから、PETを用いてプラークを検出できる。昨年3月時点では検査結果の解釈に問題があるとして承認を拒絶されていた。
 Amyvidの世界市場規模は10〜50億ドルとされている。GEとバイエル社は、ライバル製品を開発中である。

-----------------------------------------------------
U.S. gives nod to Eli Lilly's brain plaque test
http://www.reuters.com/article/2012/04/07/us-fda-lilly-amyvid-idUSBRE8360C220120407

WASHINGTON | Sat Apr 7, 2012 4:17pm EDT
(Reuters) - U.S. regulators gave the nod to an imaging test from Eli Lilly and Co. that can for the first time help doctors detect brain plaque tied to Alzheimer's disease, the company said.

The U.S. Food and Drug Administration approved the radioactive dye, called Amyvid, to help doctors rule out whether patients have Alzheimer's, the most common form of dementia, Lilly announced late on Friday.

The dye binds to clumps of a toxic protein called beta amyloid that accumulates in the brains of patients with Alzheimer's. Doctors can then see the plaque light up on a positron emission tomography, or PET, scan.

Patients with Alzheimer's always have some brain plaque, so its absence in the test would tell doctors to look for other causes of mental decline, such as depression or medications, Lilly has said.

But Lilly, which plans to sell the drug through its unit Avid Radiopharmaceuticals Inc, said the test should not be used to diagnose Alzheimer's, since brain plaque can also be tied to other neurologic conditions and may occur naturally in older people with normal mental states.

An FDA advisory panel recommended against approving the dye last year, saying doctors might have trouble interpreting scans of the plaque, and the FDA rejected Amyvid last March.

Since then, Eli Lilly said it has worked to identify better ways of training doctors to use the test.

Dr. Daniel Skovronsky, CEO of Avid, said one in five patients who are diagnosed with Alzheimer's turn out not to have the disease after an autopsy.

"The approval of Amyvid offers physicians a tool that, in conjunction with other diagnostic evaluations, can provide information to help physicians evaluate their patients," he said in the company's statement from Friday.

There is currently no cure for Alzheimer's, a mind-robbing disease that affects more than 35 million people worldwide and gets worse with age.

But an early hint that something is wrong might improve the success of drugs meant to prevent or delay disease progression, researchers believe.

Avid has been in the lead in the race for imaging agents for Alzheimer's, which are estimated to have a potential global market anywhere from $1 billion to $5 billion.

General Electric Co and Bayer AG are developing rival products.

Lilly, as well as Pfizer Inc, are the farthest along in developing experimental medicines to treat Alzheimer's. Lilly expects to release final data for its contender, solanezumab, as soon as this summer.

(Reporting by Anna Yukhananov; editing by Todd Eastham)

テーマ

関連テーマ 一覧


月別リンク

ブログ気持玉

クリックして気持ちを伝えよう!
ログインしてクリックすれば、自分のブログへのリンクが付きます。
→ログインへ
気持玉数 : 3
なるほど(納得、参考になった、ヘー) なるほど(納得、参考になった、ヘー) なるほど(納得、参考になった、ヘー)

トラックバック(0件)

タイトル (本文) ブログ名/日時

トラックバック用URL help


自分のブログにトラックバック記事作成(会員用) help

タイトル
本 文

コメント(0件)

内 容 ニックネーム/日時

コメントする help

ニックネーム
本 文
アルツハイマー病の診断造影剤を承認/FDA 医師の一分/BIGLOBEウェブリブログ
文字サイズ:       閉じる